ijms-logo

Journal Browser

Journal Browser

Sphingolipid Metabolism and Signaling in Health and Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: 28 August 2024 | Viewed by 3021

Special Issue Editor


E-Mail Website
Guest Editor
Idaho College of Osteopathic Medicine, Meridian, ID, USA
Interests: sphingolipid metabolism and signaling; obesity; diabetes; fatty liver disease; cardiometabolic syndrome

Special Issue Information

Dear Colleagues,

We kindly invite you to contribute to this IJMS Special Issue entitled ‘Sphingolipid Metabolism and Signaling in Health and Diseases’ focused on the multifaceted aspects of sphingolipids' role in maintaining health and contributing to disease pathogenesis.

Sphingolipids, a diverse and ubiquitous group of lipids, are integral to several essential cellular functions and are implicated in various dysfunction and disease states. They are not only involved in intracellular trafficking and serve as structural components of cell membranes, providing stability and fluidity to the lipid bilayer, but also play various essential roles as secondary messengers in cell signaling pathways, regulating critical processes like cell growth, proliferation, and apoptosis. Additionally, sphingolipids are pivotal in maintaining cell integrity and barrier functions in the skin and gastrointestinal tract. Dysregulation of sphingolipid metabolism and altered signaling are implicated in various pathological conditions, including neurodegenerative disorders such as ALS, Alzheimer's, and Parkinson's, as well as cancer, diabetes, obesity, and cardiometabolic disorders. Moreover, chronic inflammation and immune system dysfunctions have been associated with sphingolipid imbalances, contributing to autoimmune diseases, chronic inflammatory states related to certain conditions, and aging.

In this Special Issue, we welcome original research articles and review articles that shed light on the underlying mechanisms, regulatory pathways, and interplay of sphingolipids in different physiological and pathological contexts, as well as submissions examining potential therapeutic interventions targeting sphingolipid signaling and metabolic pathways.

Dr. Gergana M. Deevska
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ceramide
  • ceramide-1-phosphate
  • sphingosine
  • sphingosine-1-phosphate
  • sphingomyelin
  • glycosphingolipids
  • metabolic syndrome
  • obesity
  • diabetes
  • cancer
  • neurodegeneration
  • neuroinflammation
  • autoimmunity

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 1718 KiB  
Article
Wide-Targeted Semi-Quantitative Analysis of Acidic Glycosphingolipids in Cell Lines and Urine to Develop Potential Screening Biomarkers for Renal Cell Carcinoma
by Masamitsu Maekawa, Tomonori Sato, Chika Kanno, Izumi Sakamoto, Yoshihide Kawasaki, Akihiro Ito and Nariyasu Mano
Int. J. Mol. Sci. 2024, 25(7), 4098; https://doi.org/10.3390/ijms25074098 - 07 Apr 2024
Viewed by 543
Abstract
Glycosphingolipids (GSLs), mainly located in the cell membrane, play various roles in cancer cell function. GSLs have potential as renal cell carcinoma (RCC) biomarkers; however, their analysis in body fluids is challenging because of the complexity of numerous glycans and ceramides. Therefore, we [...] Read more.
Glycosphingolipids (GSLs), mainly located in the cell membrane, play various roles in cancer cell function. GSLs have potential as renal cell carcinoma (RCC) biomarkers; however, their analysis in body fluids is challenging because of the complexity of numerous glycans and ceramides. Therefore, we applied wide-targeted lipidomics using liquid chromatography–tandem mass spectrometry (LC–MS/MS) with selected reaction monitoring (SRM) based on theoretical mass to perform a comprehensive measurement of GSLs and evaluate their potency as urinary biomarkers. In semi-quantitative lipidomics, 240 SRM transitions were set based on the reported/speculated structures. We verified the feasibility of measuring GSLs in cells and medium and found that disialosyl globopentaosylceramide (DSGb5 (d18:1/16:0)) increased GSL in the ACHN medium. LC–MS/MS analysis of urine samples from clear cell RCC (ccRCC) patients and healthy controls showed a significant increase in the peak intensity of urinary DSGb5 (d18:1/16:0) in the ccRCC group compared with that in the control group. Receiver operating characteristic analysis indicated that urinary DSGb5 could serve as a sensitive and specific marker for RCC screening, with an AUC of 0.89. This study demonstrated the possibility of urinary screening using DSGb5 (d18:1/16:0). In conclusion, urinary DSGb5 (d18:1/16:0) was a potential biomarker for cancer screening, which could contribute to the treatment of RCC patients. Full article
(This article belongs to the Special Issue Sphingolipid Metabolism and Signaling in Health and Diseases)
Show Figures

Figure 1

15 pages, 2538 KiB  
Article
The Sphingolipid-Modulating Drug Opaganib Protects against Radiation-Induced Lung Inflammation and Fibrosis: Potential Uses as a Medical Countermeasure and in Cancer Radiotherapy
by Lynn W. Maines, Staci N. Keller, Ryan A. Smith, Cecelia L. Green and Charles D. Smith
Int. J. Mol. Sci. 2024, 25(4), 2322; https://doi.org/10.3390/ijms25042322 - 15 Feb 2024
Viewed by 1127
Abstract
Fibrosis is a chronic pathology resulting from excessive deposition of extracellular matrix components that leads to the loss of tissue function. Pulmonary fibrosis can follow a variety of diverse insults including ischemia, respiratory infection, or exposure to ionizing radiation. Consequently, treatments that attenuate [...] Read more.
Fibrosis is a chronic pathology resulting from excessive deposition of extracellular matrix components that leads to the loss of tissue function. Pulmonary fibrosis can follow a variety of diverse insults including ischemia, respiratory infection, or exposure to ionizing radiation. Consequently, treatments that attenuate the development of debilitating fibrosis are in desperate need across a range of conditions. Sphingolipid metabolism is a critical regulator of cell proliferation, apoptosis, autophagy, and pathologic inflammation, processes that are all involved in fibrosis. Opaganib (formerly ABC294640) is the first-in-class investigational drug targeting sphingolipid metabolism for the treatment of cancer and inflammatory diseases. Opaganib inhibits key enzymes in sphingolipid metabolism, including sphingosine kinase-2 and dihydroceramide desaturase, thereby reducing inflammation and promoting autophagy. Herein, we demonstrate in mouse models of lung damage following exposure to ionizing radiation that opaganib significantly improved long-term survival associated with reduced lung fibrosis, suppression of granulocyte infiltration, and reduced expression of IL-6 and TNFα at 180 days after radiation. These data further demonstrate that sphingolipid metabolism is a critical regulator of fibrogenesis, and specifically show that opaganib suppresses radiation-induced pulmonary inflammation and fibrosis. Because opaganib has demonstrated an excellent safety profile during clinical testing in other diseases (cancer and COVID-19), the present studies support additional clinical trials with this drug in patients at risk for pulmonary fibrosis. Full article
(This article belongs to the Special Issue Sphingolipid Metabolism and Signaling in Health and Diseases)
Show Figures

Figure 1

Review

Jump to: Research

15 pages, 1237 KiB  
Review
The Implication of Sphingolipids in Viral Infections
by Sanya Thomas, Stephen Varghese Samuel, Annmarie Hoch, Caitlin Syphurs and Joann Diray-Arce
Int. J. Mol. Sci. 2023, 24(24), 17303; https://doi.org/10.3390/ijms242417303 - 09 Dec 2023
Cited by 2 | Viewed by 1043
Abstract
Sphingolipids are involved in cell signaling and metabolic pathways, and their metabolites play a critical role in host defense against intracellular pathogens. Here, we review the known mechanisms of sphingolipids in viral infections and discuss the potential implication of the study of sphingolipid [...] Read more.
Sphingolipids are involved in cell signaling and metabolic pathways, and their metabolites play a critical role in host defense against intracellular pathogens. Here, we review the known mechanisms of sphingolipids in viral infections and discuss the potential implication of the study of sphingolipid metabolism in vaccine and therapeutic development. Full article
(This article belongs to the Special Issue Sphingolipid Metabolism and Signaling in Health and Diseases)
Show Figures

Figure 1

Back to TopTop